Low Dose Metronomic Poly-chemotherapy for Metastatic CRC
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study investigates the activity of a new regimen of treatment for patients with
metastatic colorectal carcinoma. This includes a combination of well-known chemotherapy
agents and anti-inflammatory agents, when administered orally at low daily doses and without
planed brakes (Low Dose Metronomic regimen), in contrast with the conventional and already
exhausted regimens of treatment at Maximal Tolerated Doses (MTD) which required pre-planned
brakes between treatment days.